Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NumeralJSE:XII 19 Debt-to-Equity is 5.57 as of Feb. 2026. GuruFocus rates JSE:XII with a GF Score™ of 19/100. The stock has 7 warning signs investors should review. Among 811 Drug Manufacturers companies, Numeral ranks worse than 98.4% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Numeral's Debt-to-Equity or its related term are showing as below:
JSE:XII'
s Debt-to-Equity Range Over the Past 10 Years
Min: -4.15 Med: -0.73 Max: 5.57
Current: 5.57
During the past 13 years, the highest Debt-to-Equity Ratio of Numeral was 5.57. The lowest was -4.15. And the median was -0.73.
JSE:XII's Debt-to-Equity is ranked worse than 98.4% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs JSE:XII: 5.57
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Numeral Debt-to-Equity Related Terms
Numeral Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Numeral's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:XII vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Numeral's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Numeral Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Numeral's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Numeral's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Numeral (JSE:XII) has a Debt-to-Equity of 5.57 as of Feb. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Numeral and its competitors. According to the industry distribution chart, Numeral ranks #798 out of 811 companies in the Drug Manufacturers industry, placing it in the top 98.4%.
Is Numeral's Debt-to-Equity too high?
Numeral's current Debt-to-Equity is 5.57. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Numeral's value of 5.57 is 1889.3% above this industry median. Based on the distribution chart, Numeral ranks #798 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Numeral has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Numeral's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Numeral ranks #798 out of 811 companies for Debt-to-Equity. This places Numeral in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Numeral's value of 5.57 is 1889.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Numeral's current Debt-to-Equity of 5.57 is 1889.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Numeral and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Numeral's current Debt-to-Equity is 5.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Numeral stock overvalued right now?
Numeral (JSE:XII) has a current Debt-to-Equity of 5.57. The current Debt-to-Equity is 5.57 and 1889.3% above the Drug Manufacturers industry median of 0.28. Numeral's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Numeral (JSE:XII), the current Debt-to-Equity is 5.57 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Numeral Ltd is an investment holding company based in Mauritius with a focus on fintech, biotechnology, and asset management. Geographically it has a presence in countries across Africa, Europe and Asia. The majority of its revenue is generated in the form of Trading income.
19GF Score
Get the complete analysis for JSE:XII
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:XII has been successfully added to your 
